Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 2/20 | 0.84 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.65 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.65 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.65 |
| ▸ | HMGCR | P04035 | 3/20 | 0.62 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.61 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.41 |
| ▸ | FABP4 | P15090 | 1/20 | 0.40 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | ESR1 | P03372 | 1/20 | 0.37 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.37 |
| ▸ | TNKS | O95271 | 1/20 | 0.36 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.36 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6283353 | 1.00 | RXRA (0.84) | RXRANR1I2NR4A2PDE4DHMGCR | |
| SCHEMBL6337258 | 0.89 | RXRA (0.71) | RXRANR1I2NR4A2PDE4DHMGCR | |
| SCHEMBL6284297 | 0.87 | RXRA (0.68) | RXRANR1I2NR4A2PDE4DHMGCR | |
| SCHEMBL6284295 | 0.87 | RXRA (0.68) | RXRANR1I2NR4A2PDE4DHMGCR | |
| SCHEMBL13991530 | 0.87 | RXRA (0.68) | RXRANR1I2NR4A2PDE4DHMGCR | |
| SCHEMBL7171504 | 0.86 | RXRA (0.67) | RXRANR1I2NR4A2PDE4DHMGCR | |
| SCHEMBL7171838 | 0.86 | RXRA (0.67) | RXRANR1I2NR4A2PDE4DHMGCR | |
| SCHEMBL29466456 | 0.85 | RXRA (0.75) | RXRANR1I2NR4A2PDE4DHMGCR | |
| SCHEMBL1844436 | 0.85 | RXRA (0.75) | RXRANR1I2NR4A2PDE4DHMGCR | |
| SCHEMBL1843198 | 0.85 | RXRA (0.75) | RXRANR1I2NR4A2PDE4DHMGCR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012140490-A2 | PROCESS FOR PREPARING QUINOLINE DERIVATIVE | AUROBINDO PHARMA LIMITED (IN) | 2012-10-18 | — | — | WO | disclosed |
| US-6909003-B2 | Process for the manufacture of organic compounds | NOVARTIS AG (CH) | 2005-06-21 | — | — | US | disclosed |
| US-20030233001-A1 | Process for the manufacture of organic compounds | NOVARTIS AG (CH) | 2003-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030233001-A1 | Process for the manufacture of organic compounds | CYP11B2, CYP11B1, HSD17B12 | RXRA 2789/4885NR1I2 2014/4885NR4A2 2924/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.